Elanco Animal Health (ELAN) said Tuesday it was partnering with MedGene to help commercialize the company's vaccine to help prevent avian influenza in dairy cattle.
Medgene previously met all of the US Department of Agriculture's requirements for its bovine vaccine platform technology, which is now in the final stages of review ahead of an expected conditional license approval, the companies said.
The prior USDA authorization also allowed Medgene to accelerate development of its H5N1 vaccine as well as adapting its existing vaccine manufacturing to protect the US dairy herd, the companies said.
Elanco shares were falling over 7% in early Tuesday trading after the company reported Q4 earnings that missed Wall Street expectations and also guided 2025 results below analyst consensus calls.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。